Clinical trial NCT00609999: Ph I Dasatinib + Erlotinib in Recurrent MG
Official title: Phase I Study of Dasatinib Plus Erlotinib in Recurrent Malignant Glioma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Glioblastoma
Gliosarcoma
Keywords: Glioblastoma
Gliosarcoma
GBM
Recurrent MG
Erlotinib
Dasatinib
Brain tumor
Malignant glioma
Tarceva
Sprycel
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Bristol-Myers Squibb
name: Genentech, Inc.
First posted: 2008-02-07
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Primary:

To determine maximum tolerated dose \& dose limiting toxicity of dasatinib when combined w erlotinib among pts w recurrent MG

Secondary:

To further evaluate safety \& tolerability of dasatinib + erlotinib To evaluate pharmacokinetics of dasatinib when administered w erlotinib among recurrent MG pts who are on \& not on CYP-3A enzyme inducing anti-epileptic drugs To evaluate for anti-tumor activity with this regimen in this patient population

Detailed description: Tarceva administered on continuous oral dosing schedule at 150 mg/day for pts not on EIAEDs \& 450 mg/day for pts on EIAEDs. Starting dose level of dasatinib will be 100 mg once day via continuous oral daily dosing. Dasatinib will be increased in successive cohorts of enrolled pts. Pts will remain on treatment until excessive toxicity, progressive disease, withdrawal of consent/death.

Pts have confirmed diagnosis of recurrent/progressive WHO gr IV MG / WHO grade III MG. Phase I 3+3 dose escalation design w 2 independently escalated stratum: stratum A-pts not on CYP3A-enzyme inducing anti-epileptic drugs; stratum B-pts on EIAEDs. Assessment of safety will be based mainly on frequency of adverse events, particularly adverse events leading to discontinuation of treatment \& on number of significant lab abnormalities.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of recurrent/progressive WHO grade IV MG or WHO grade III MG. Pts with prior low-grade glioma are eligible if histologic assessment demonstrates transformation to WHO grade III / IV MG
* \>18 yrs
* Karnofsky Performance Status \>70 percent
* Pts presenting in 1st, 2nd / 3rd relapse. Prior therapy must have included external beam XRT
* Adequate bone marrow, liver \& renal function as assessed by following:
* Hemoglobin\>9.0g/dl
* ANC\>1,500/mm3
* Platelet count\>100,000/mm3
* Total bilirubin\<1.5 x ULN
* ALT \& AST\<2.5 x ULN
* INR\<1.5 or PT/PTT within normal limits. Pts receiving anti-coagulation treatment w low-molecular weight heparin allowed to participate, oral warfarin is not permitted
* Creatinine\<1.5 x ULN
* Serum Na, K+, Mg2+, Phosphate \& Ca2+ \>LLN
* Interval\<2 wks between prior surgical resection \& initiation of study regimen
* Interval \<12 weeks from completion of standard, daily XRT, unless one of following occurs: new area of enhancement on MRI imaging that is outside XRT field; biopsy proven recurrent tumor; / radiographic evidence of progressive tumor on 2 consecutive scans \>4 wks apart.
* Interval \<4weeks from prior chemotherapy unless there is unequivocal evidence of tumor progression \& pt has recovered from all anticipated toxicities from prior therapy
* Interval \<4weeks from prior investigational agent unless there is unequivocal evidence of tumor progression \& pt has recovered from all anticipated toxicities from prior therapy
* Signed written informed consent including HIPAA according to institutional guidelines. Signed informed consent must be obtained prior to any study specific procedures
* If sexually active, pts will take contraceptive measures for duration of treatments \& for 4 weeks following discontinuation of dasatinib \& Erlotinib.
* Women of childbearing potential must have negative serum or urine pregnancy test within 72 hrs prior to start of study drug administration

Exclusion Criteria:

* No prior dasatinib / oral EGFR-inhibitor therapy
* Pregnancy/breast feeding
* History of significant concurrent illness

  -\>3 prior episodes of progressive disease
* Significant cardiac disease
* Excessive risk of bleeding as defined by stroke \<6 months, history of CNS / intraocular bleed,/ septic endocarditis.
* Concurrent severe and/or uncontrolled medical disease that could compromise participation in study including any of following: pleural / pericardial effusion of any grade; uncontrolled diabetes; uncontrolled hypertension; active clinically serious infection \>CTCAEv3 Gr2 requiring active intervention; history of clinically-significant bleeding diathesis or coagulopathy including platelet function disorder or acquired bleeding disorder within 1yr; impairment of GI function /GI disease that may significantly alter absorption of study regimen; ongoing or recent significant gastrointestinal bleeding
* Thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks \<6 months
* Any hemorrhage/bleeding event \>CTCAEv3AE Gr3 within 4wks of 1st dose of study drug
* Serious non-healing wound, ulcer, /bone fracture
* Major surgery, open biopsy /significant traumatic injury \<4 weeks of 1st study drug
* Known HIV infection/chronic Hepatitis B/C
* Pt is \<3yrs free of another primary malignancy except: if other primary malignancy is either not currently clinically significant/does not require active intervention. Existence of any other malignant disease is not allowed.
* Pts unwilling to/unable to comply with protocol including ability to swallow whole pills/presence of any malabsorption syndrome
* Concurrent administration of warfarin, rifampin/St. John's Wort
* Subjects w hypokalemia/hypomagnesemia if it cannot be corrected
* Prisoners/subjects who are compulsorily detained for treatment of either psychiatric/physical illness

Primary outcomes:
measure: To determine MTD & DLT of Dasatinib when combined w Erlotinib among pts w Recurrent MG
timeFrame: 12 months
Secondary outcomes:
measure: To further evaluate safety & tolerability of Dasatinib + Erlotinib
timeFrame: 12 months
measure: To evaluate the PK of Dasatinib when administered w Erlotinib among Recurrent MG pts who are on & not on EIAEDs
timeFrame: 12 months
measure: To evaluate for anti-tumor activity w this regimen in this pt population
timeFrame: 12 months
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Health System
state: North Carolina
Study officials:
affiliation: Duke Health
name: Annick Desjardins, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References: